Establishment Labs Holdings Inc. ( ESTA ) NASDAQ Capital Market

Cena: 35.98 ( -1.64% )

Aktualizacja 06-24 20:26
NASDAQ Capital Market
Branża: Medical - Devices
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 908
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 87%
Ilość akcji: 27 191 864
Debiut giełdowy: 2018-07-19
WWW: https://www.establishmentlabs.com
CEO: Mr. Juan Jose Chacon Quiros
Adres: Building B15 and 25
Siedziba: None Alajuela
ISIN: VGG312491084
Opis firmy:

Establishment Labs Holdings Inc., firma zajmująca się technologią medyczną, produkuje i sprzedaje urządzenia medyczne dla estetycznej i rekonstrukcyjnej chirurgii plastycznej. Firma oferuje przede wszystkim silikonowe implanty piersi pod marką Implants Motiva Implants. Zapewnia również Motiva Ergonix i Motiva Ergoniksix2 wrażliwe na grawitację okrągłe miękkie silikonowe implanty piersi wypełnione żelami; oraz Motiva Flora Expander, ekspander tkanki piersi, a także rozpowszechnia linię produktów do autologicznego pozyskiwania i redystrybucji tkanki tłuszczowej. Firma sprzedaje swoje produkty za pośrednictwem ekskluzywnych dystrybutorów i bezpośrednich sił sprzedaży w Europie, Ameryce Łacińskiej, Azji i Pacyfiku i na arenie międzynarodowej. Establishment Labs Holdings Inc. został zarejestrowany w 2004 r. I ma siedzibę w Alajueli, Kostaryka.

Wskaźniki finansowe
Kapitalizacja (USD) 1 040 444 454
Aktywa: 282 685 000
Cena: 35.98
Wskaźnik Altman Z-Score: 1.5
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -11.5
Ilość akcji w obrocie: 87%
Średni wolumen: 499 001
Ilość akcji 28 917 300
Wskaźniki finansowe
Przychody TTM 153 071 000
Zobowiązania: 249 975 000
Przedział 52 tyg.: 26.56 - 52.41
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -3.1
P/E branży: 26.8
Beta: 1.208
Raport okresowy: 2025-08-04
WWW: https://www.establishmentlabs.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Rajbir Singh Denhoy Chief Financial Officer 533 202 1971
Mr. S. Ross Mansbach General Counsel, Chief Compliance Officer & Chief Human Resources Officer 509 758 1967
Mr. Salvador Santos Dada Head of Special Projects 468 616 1982
Mr. Juan Jose Chacon Quiros Founder, Chief Executive Officer & Executive Director 1 092 370 1973
Ms. Rosalyn Cole d'Incelli SVice President of Global Clinical, Medical & US Regulatory Affairs 0 0
Mr. Ivan Bilic Senior Vice President of Commercial Operations - OUS 0 0
Mr. Jeff Ehrhard Senior Vice President & GM of North America 0 0
Ms. Neeta Toprani Corporate Secretary 0 0
Mr. Roberto de Mezerville Chief Technology Officer 0 1981
Wiadomości dla Establishment Labs Holdings Inc.
Tytuł Treść Źródło Aktualizacja Link
Establishment Labs Holdings Inc. (ESTA) Q4 2024 Earnings Call Transcript Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Raj Denhoy - CFO Juan Chacón-Quirós - CEO Peter Caldini - President Conference Call Participants Anthony Petrone - Mizuho Group Allen Gong - JPMorgan Josh Jennings - TD Cowen Marie Thibault - BTIG Joanne Wuensch - Citibank Matt Taylor - Jefferies Harrison Parsons - Stephens Inc Operator Good afternoon. Welcome to Establishment Labs Fourth Quarter 2024 Earnings Call. seekingalpha.com 2025-02-26 22:56:03 Czytaj oryginał (ang.)
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Lags Revenue Estimates Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.79 per share a year ago. zacks.com 2025-02-26 20:11:07 Czytaj oryginał (ang.)
Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2024 and reaffirmed 2025 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $44.5 million, consistent with preannouncement on January 13. Motiva Implants approved and la. businesswire.com 2025-02-26 18:00:00 Czytaj oryginał (ang.)
Establishment Labs to Present at Citi's 2025 Unplugged Medtech and Life Sciences Access Day NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in a fireside chat at Citi's 2025 Unplugged Medtech and Life Sciences Access Day. Juan José Chacón-Quirós, Chief Executive Officer and Founder; Peter Caldini, President; and Raj Denhoy, Chief Financial Officer, are scheduled to present on Thursday,. businesswire.com 2025-02-21 10:00:00 Czytaj oryginał (ang.)
Establishment Labs Launches Preservé™ NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced it has launched Preservé™ in Brazil, the first country in its global rollout. Preservé is the second product in the Company's minimally invasive platform, building upon the technologies and techniques developed with Mia Femtech®, Establishment Labs' minimally invasive experience. “The. businesswire.com 2025-02-18 10:00:00 Czytaj oryginał (ang.)
Establishment Labs to Announce Fourth Quarter 2024 Financial Results on February 26 NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2024, after the market closes on Wednesday, February 26, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. businesswire.com 2025-02-14 10:00:00 Czytaj oryginał (ang.)
Establishment Labs to Present at the 43rd Annual J.P. Morgan Healthcare Conference NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 3:45 p.m. Pacific Time. A live webcast of the presentation. businesswire.com 2025-01-07 10:00:00 Czytaj oryginał (ang.)
Establishment Labs Holdings Inc. (ESTA) Q3 2024 Earnings Call Transcript Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Rajbir Denhoy - Chief Financial Officer Juan Jose - CEO and Founder Conference Call Participants Allen Gong - JPMorgan Matt Taylor - Jefferies Sam Eiber - BTIG Anthony Pettinari - Citi Josh Jennings - TD Cowen Anthony Petrone - Mizuho Group Operator Good afternoon. Welcome to Establishment Labs Third Quarter 2024 Earnings Conference Call. seekingalpha.com 2024-11-09 10:55:27 Czytaj oryginał (ang.)
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Misses Revenue Estimates Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.12 per share a year ago. zacks.com 2024-11-07 20:21:09 Czytaj oryginał (ang.)
Establishment Labs Announces $50 Million Registered Direct Offering NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with select purchasers for the purchase of 765,696 common shares and pre-funded warrants to purchase up to 328,161 common shares in a registered direct offering for a. businesswire.com 2024-11-07 19:20:00 Czytaj oryginał (ang.)
Establishment Labs Announces Three-Year Mia Femtech Clinical Results at 9th World Symposium on Ergonomic Implants NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Barcelona, Spain. The Mia Femtech Clinical Study is an IRB-approved prospective study that enrolled 100 subjects betwee. businesswire.com 2024-10-31 10:00:00 Czytaj oryginał (ang.)
Establishment Labs Holdings Inc (ESTA) Stock Price Up 9.25% on Oct 2 Shares of Establishment Labs Holdings Inc (ESTA, Financial) surged 9.25% in mid-day trading on Oct 2. The stock reached an intraday high of $44.42, before settling at $44.31, up from its previous close of $40.56. gurufocus.com 2024-10-02 16:07:23 Czytaj oryginał (ang.)
Establishment Labs Receives U.S. FDA Approval for Motiva Implants NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast augmentation. “Today's approval is transformative for breast aesthetics in. businesswire.com 2024-09-26 21:02:00 Czytaj oryginał (ang.)
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago. zacks.com 2024-08-06 22:16:49 Czytaj oryginał (ang.)
Establishment Labs to Announce Second Quarter 2024 Financial Results on August 6 NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after the market closes on Tuesday, August 6, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (800) 715-9871 (U.S. and Can. businesswire.com 2024-07-24 12:00:00 Czytaj oryginał (ang.)
Establishment Labs (ESTA) Surges 7.4%: Is This an Indication of Further Gains? Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com 2024-06-25 09:35:16 Czytaj oryginał (ang.)
Establishment Labs Announces Participation in Two Upcoming Investment Conferences NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences. Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2024 Jefferies Global Healthcare Conference being held June 5-6, 2024. Mr. Chacón. businesswire.com 2024-05-23 12:00:00 Czytaj oryginał (ang.)
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.48 per share a year ago. zacks.com 2024-05-08 22:11:10 Czytaj oryginał (ang.)
Establishment Labs Notes Presentation of 4-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2024 NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include four-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the re. businesswire.com 2024-05-02 12:30:00 Czytaj oryginał (ang.)
Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants. businesswire.com 2024-05-01 12:30:00 Czytaj oryginał (ang.)
Establishment Labs to Announce First Quarter 2024 Financial Results on May 8 NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Cana. businesswire.com 2024-04-24 12:30:00 Czytaj oryginał (ang.)
Establishment Labs Announces Participation in The Aesthetic Meeting 2024 NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2024, which is being held May 2-5 in Vancouver, BC Canada. At the meeting, Dr. Caroline Glicksman, the Medical Director and an Investigator in the Motiva US IDE Study, will present an update on the clinical trial after comp. businesswire.com 2024-04-17 12:30:00 Czytaj oryginał (ang.)
Establishment Labs Holdings Inc. (ESTA) Q4 2023 Earnings Call Transcript Establishment Labs Holdings Inc. (ESTA) Q4 2023 Earnings Call Transcript seekingalpha.com 2024-02-29 01:45:21 Czytaj oryginał (ang.)
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.55 per share a year ago. zacks.com 2024-02-28 20:31:03 Czytaj oryginał (ang.)
Establishment Labs Announces Participation in Two Upcoming Investment Conferences NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences. Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in Citi's 2024 Unplugged Medtech and Life Sciences Access Day. Mr. Chacón-Quirós and Mr. businesswire.com 2024-02-23 10:00:00 Czytaj oryginał (ang.)
Establishment Labs Announces Amended Credit Facility with Oaktree NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The terms on the two tranches already drawn under the facility, which total $175 million, are unchanged. The remaining two $25 million tranches are amended as follow. businesswire.com 2024-02-22 10:00:00 Czytaj oryginał (ang.)
Analysts Estimate Establishment Labs Holdings Inc. (ESTA) to Report a Decline in Earnings: What to Look Out for Establishment Labs Holdings Inc. (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-02-21 13:06:13 Czytaj oryginał (ang.)